Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dactinomycin + etoposide
- Development stage
- Unknown
- Lead developer
- Recordati
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Dactinomycin + etoposide is a chemotherapy combination used primarily in the treatment of gestational trophoblastic neoplasia (GTN) and testicular cancer. This combination is often part of multi-agent regimens such as EMA/CO (etoposide, methotrexate, dactinomycin, cyclophosphamide, vincristine) or APE (actinomycin D, cisplatin, and etoposide). Dactinomycin works by binding to DNA and inhibiting RNA synthesis, while etoposide is believed to produce cytotoxic effects through DNA binding and inhibition of topoisomerase II.
- Other names
- actinomycin D + etoposide
02
Targets
TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)DNA
Beyond the preview
Go deeper on dactinomycin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dactinomycin + etoposide.